EV / EBITDA společnosti Hutchison China MediTech
Jaká je hodnota metriky EV / EBITDA společnosti Hutchison China MediTech?
Hodnota metriky EV / EBITDA společnosti Hutchison China MediTech Ltd. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na LSE ve srovnání se společností Hutchison China MediTech
Čemu se věnuje společnost Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Firmy s metrikou ev / ebitda podobnou společnosti Hutchison China MediTech
- Hodnota metriky EV / EBITDA společnosti Phoenitron je N/A
- Hodnota metriky EV / EBITDA společnosti Spielvereinigung Unterhaching FuSball GmbH & Co. KGaA je N/A
- Hodnota metriky EV / EBITDA společnosti Macquarie Infrastructure je N/A
- Hodnota metriky EV / EBITDA společnosti Mason Graphite je N/A
- Hodnota metriky EV / EBITDA společnosti Omnia Metals Ltd je N/A
- Hodnota metriky EV / EBITDA společnosti Charle Co je N/A
- Hodnota metriky EV / EBITDA společnosti Hutchison China MediTech je N/A
- Hodnota metriky EV / EBITDA společnosti Ora Gold je N/A
- Hodnota metriky EV / EBITDA společnosti Nevada Zinc je N/A
- Hodnota metriky EV / EBITDA společnosti Jianzhong Construction Development je N/A
- Hodnota metriky EV / EBITDA společnosti Canterbury Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Great Thunder Gold je N/A
- Hodnota metriky EV / EBITDA společnosti Wonderful Sky je N/A